Cargando…

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

BACKGROUND: Breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough progress of novel anti-HER2 antibody-drug conjugates. HER2 expression is examined in patients with HER2-low BC and their distant metastases in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Mengyuan, Li, Ming, Lv, Hong, Zhou, Shuling, Xu, Xiaoli, Shui, Ruohong, Yang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347880/
https://www.ncbi.nlm.nih.gov/pubmed/37442945
http://dx.doi.org/10.1186/s12885-023-11134-4
_version_ 1785073620049985536
author Cai, Mengyuan
Li, Ming
Lv, Hong
Zhou, Shuling
Xu, Xiaoli
Shui, Ruohong
Yang, Wentao
author_facet Cai, Mengyuan
Li, Ming
Lv, Hong
Zhou, Shuling
Xu, Xiaoli
Shui, Ruohong
Yang, Wentao
author_sort Cai, Mengyuan
collection PubMed
description BACKGROUND: Breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough progress of novel anti-HER2 antibody-drug conjugates. HER2 expression is examined in patients with HER2-low BC and their distant metastases in this study, so as to further clarify the dynamic characteristics of HER2 low status in the process of disease progression. METHODS: Patients diagnosed with HER2 low breast cancer (defined as IHC1+ or IHC2+/ISH-) between 2012 and 2021 were included in this study. We evaluated HER2 expression of primary sites and metastatic sites, compared the impact of different clinicopathological parameters on HER2 status of metastases and compared the overall survival and disease-free survival of patients with different HER2 status in metastases. RESULTS: Ninety-eight patients were included. All HER2 IHC scores were confirmed and the consistent rate with the original pathological report was 81.1%. 27.6% of the patients showed different HER2 status in metastases. The HER2 discordance rate differed among different metastatic sites (p = 0.040). The higher the T stage of the primary BC, the higher the rate of HER2 discordance was observed (p = 0.042). For the specimen type of metastasis, HER2 discordant rate was higher in surgical specimen than biopsy (p = 0.050). No difference of HER2 discordance rate was found between HER2-1+ and HER2-2+ patients. But comparing HER2 IHC score, HER2-2+ patients were less likely to have consistent metastatic HER2 levels than HER2-1+ patients (p = 0.006). No difference in survival outcomes was observed between patients with different HER2 status in metastases. CONCLUSIONS: There is a possibility of HER2 expression alteration in the metastases of HER2-low breast cancer. And the rate of altered HER2 low expression was different among different metastatic sites, different T stages of primary BC and specimen type of metastasis. No prognostic significance was observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11134-4.
format Online
Article
Text
id pubmed-10347880
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103478802023-07-15 HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases Cai, Mengyuan Li, Ming Lv, Hong Zhou, Shuling Xu, Xiaoli Shui, Ruohong Yang, Wentao BMC Cancer Research BACKGROUND: Breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough progress of novel anti-HER2 antibody-drug conjugates. HER2 expression is examined in patients with HER2-low BC and their distant metastases in this study, so as to further clarify the dynamic characteristics of HER2 low status in the process of disease progression. METHODS: Patients diagnosed with HER2 low breast cancer (defined as IHC1+ or IHC2+/ISH-) between 2012 and 2021 were included in this study. We evaluated HER2 expression of primary sites and metastatic sites, compared the impact of different clinicopathological parameters on HER2 status of metastases and compared the overall survival and disease-free survival of patients with different HER2 status in metastases. RESULTS: Ninety-eight patients were included. All HER2 IHC scores were confirmed and the consistent rate with the original pathological report was 81.1%. 27.6% of the patients showed different HER2 status in metastases. The HER2 discordance rate differed among different metastatic sites (p = 0.040). The higher the T stage of the primary BC, the higher the rate of HER2 discordance was observed (p = 0.042). For the specimen type of metastasis, HER2 discordant rate was higher in surgical specimen than biopsy (p = 0.050). No difference of HER2 discordance rate was found between HER2-1+ and HER2-2+ patients. But comparing HER2 IHC score, HER2-2+ patients were less likely to have consistent metastatic HER2 levels than HER2-1+ patients (p = 0.006). No difference in survival outcomes was observed between patients with different HER2 status in metastases. CONCLUSIONS: There is a possibility of HER2 expression alteration in the metastases of HER2-low breast cancer. And the rate of altered HER2 low expression was different among different metastatic sites, different T stages of primary BC and specimen type of metastasis. No prognostic significance was observed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11134-4. BioMed Central 2023-07-13 /pmc/articles/PMC10347880/ /pubmed/37442945 http://dx.doi.org/10.1186/s12885-023-11134-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cai, Mengyuan
Li, Ming
Lv, Hong
Zhou, Shuling
Xu, Xiaoli
Shui, Ruohong
Yang, Wentao
HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
title HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
title_full HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
title_fullStr HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
title_full_unstemmed HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
title_short HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
title_sort her2-low breast cancer: evolution of her2 expression from primary tumor to distant metastases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347880/
https://www.ncbi.nlm.nih.gov/pubmed/37442945
http://dx.doi.org/10.1186/s12885-023-11134-4
work_keys_str_mv AT caimengyuan her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases
AT liming her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases
AT lvhong her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases
AT zhoushuling her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases
AT xuxiaoli her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases
AT shuiruohong her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases
AT yangwentao her2lowbreastcancerevolutionofher2expressionfromprimarytumortodistantmetastases